Diplomat Pharmacy, Inc. (NYSE:DPLO) was upgraded by equities research analysts at TheStreet from a “d+” rating to a “c-” rating in a research report issued on Thursday.

Several other research firms have also commented on DPLO. Mizuho upped their price target on shares of Diplomat Pharmacy from $17.00 to $19.00 and gave the company a “neutral” rating in a research report on Tuesday, May 16th. Leerink Swann reaffirmed a “market perform” rating and set a $18.00 price target (up previously from $16.00) on shares of Diplomat Pharmacy in a research report on Wednesday, May 17th. Bank of America Corporation upped their price target on shares of Diplomat Pharmacy from $17.00 to $18.50 and gave the company a “neutral” rating in a research report on Thursday, May 25th. Barclays PLC set a $20.00 price target on shares of Diplomat Pharmacy and gave the company a “buy” rating in a research report on Tuesday, May 9th. Finally, Cowen and Company upped their price target on shares of Diplomat Pharmacy from $12.00 to $17.00 and gave the company a “market perform” rating in a research report on Tuesday, May 9th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and two have assigned a buy rating to the stock. Diplomat Pharmacy currently has an average rating of “Hold” and an average target price of $17.89.

Diplomat Pharmacy (NYSE DPLO) opened at 16.20 on Thursday. The stock has a market cap of $1.09 billion, a P/E ratio of 88.52 and a beta of 0.66. The stock has a 50 day moving average of $15.43 and a 200 day moving average of $15.74. Diplomat Pharmacy has a 1-year low of $12.25 and a 1-year high of $34.80.

Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings results on Monday, August 7th. The company reported $0.25 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.15 by $0.10. Diplomat Pharmacy had a net margin of 0.27% and a return on equity of 7.97%. The firm had revenue of $1.13 billion during the quarter, compared to analyst estimates of $1.14 billion. During the same quarter in the prior year, the firm earned $0.23 EPS. The business’s revenue for the quarter was up 3.5% compared to the same quarter last year. Equities analysts anticipate that Diplomat Pharmacy will post $0.75 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.dailypolitical.com/2017/08/12/diplomat-pharmacy-inc-dplo-upgraded-to-c-at-thestreet.html.

Large investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its stake in Diplomat Pharmacy by 73.1% in the first quarter. JPMorgan Chase & Co. now owns 7,235 shares of the company’s stock valued at $116,000 after buying an additional 3,056 shares in the last quarter. State of Alaska Department of Revenue raised its stake in Diplomat Pharmacy by 80.0% in the second quarter. State of Alaska Department of Revenue now owns 8,623 shares of the company’s stock valued at $127,000 after buying an additional 3,833 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in Diplomat Pharmacy by 46.7% in the second quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock valued at $130,000 after buying an additional 2,794 shares in the last quarter. BNP Paribas Arbitrage SA raised its stake in Diplomat Pharmacy by 13.8% in the first quarter. BNP Paribas Arbitrage SA now owns 8,876 shares of the company’s stock valued at $142,000 after buying an additional 1,073 shares in the last quarter. Finally, Municipal Employees Retirement System of Michigan raised its stake in Diplomat Pharmacy by 4.9% in the second quarter. Municipal Employees Retirement System of Michigan now owns 10,250 shares of the company’s stock valued at $152,000 after buying an additional 480 shares in the last quarter. 72.02% of the stock is owned by institutional investors.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.